Target Name: OGA
NCBI ID: G10724
Review Report on OGA Target / Biomarker Content of Review Report on OGA Target / Biomarker
OGA
Other Name(s): beta-N-acetylhexosaminidase | meningioma expressed antigen 5 (hyaluronidase) | OGA_HUMAN | OGA variant 1 | beta-hexosaminidase | nuclear cytoplasmic O-GlcNAcase and acetyltransferase | MEA5 | O-GlcNAcase | N-acetyl-beta-D-glucosaminidase | Nuclear cytoplasmic O-GlcNAcase and acetyltransferase | FLJ11229 | Bifunctional protein NCOAT | Hexosaminidase C | N-acetyl-beta-glucosaminidase | MGEA5 | Histone acetyltransferase | Glycoside hydrolase O-GlcNAcase | Beta-N-acetylglucosaminidase | Protein O-GlcNAcase | Hyaluronidase in meningioma | NCOAT | meningioma-expressed antigen 5 | Protein O-GlcNAcase (isoform a) | FLJ23355 | HAT | Meningioma-expressed antigen 5 | hyaluronidase in meningioma | Beta-hexosaminidase | beta-N-acetylglucosaminidase | bifunctional protein NCOAT | KIAA0679 | O-GlcNAcase, transcript variant 1 | Beta-N-acetylhexosaminidase

Understanding OGA: Potential Therapeutic Targets for Cancer and Neurodegenerative Diseases

OGA (beta-N-acetylhexosaminidase) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and liver. It is a key enzyme in the glycosylation process, which is the final step in the formation of certain proteins. OGA is also involved in the regulation of cellular signaling pathways and is a potential drug target in the treatment of various diseases.

OGA is a 21-kDa protein that is composed of two distinct subunits, alpha and beta subunits. The alpha subunit consists of 125 amino acids and is responsible for catalyzing the acetylation of the N-acetyl groups on the alpha-amino terminal of specific amino acids. The beta subunit consists of 54 amino acids and is responsible for regulating the activity of the alpha subunit.

OGA is involved in the regulation of several cellular signaling pathways, including the TGF-beta pathway, the PI3K/Akt pathway, and the JAK/STAT signaling pathway. These pathways are involved in a wide range of cellular processes, including cell growth, differentiation, and inflammation. OGA has been shown to play a key role in the regulation of each of these pathways and is a potential drug target in the treatment of various diseases.

One of the potential benefits of targeting OGA is its potential to disrupt the formation of certain proteins that are involved in cancer. Many proteins that are involved in cancer development, such as insulin-like growth factor 1 (IGF-1), have been shown to be modified by OGA. This modification is thought to play a role in the regulation of IGF-1 signaling and may contribute to the development and progression of cancer. Targeting OGA may therefore be a useful way to treat certain types of cancer.

Another potential benefit of targeting OGA is its potential to treat neurodegenerative diseases. OGA is involved in the regulation of several neurotransmitter systems, including dopamine and nitric oxide. Its role in these systems makes it a potential target for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, OGA is also a potential biomarker for a variety of diseases. The modification of OGA by certain diseases, such as cancer, has been shown to be associated with the development and progression of these diseases. Therefore, measuring the level of OGA in tissues or fluids, such as blood or urine, may be a useful diagnostic tool for these diseases.

Overall, OGA is a protein that is involved in several cellular signaling pathways and has been shown to play a key role in the regulation of various cellular processes. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of OGA in these processes and to develop effective treatments.

Protein Name: O-GlcNAcase

Functions: Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro) (PubMed:11148210). Does not bind acetyl-CoA and does not have histone acetyltransferase activity (PubMed:24088714)

The "OGA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OGA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OGDH | OGDHL | OGFOD1 | OGFOD2 | OGFOD3 | OGFR | OGFR-AS1 | OGFRL1 | OGFRP1 | OGG1 | OGN | OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1